Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 23Liver Neoplasms 4Recurrence 2Sarcoma 1Recurrence Hepatocellular Carcinoma 1Pleural Neoplasms 1Pancreatic Adenocarcinoma 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Neoplasm Recurrence, Local 1Mediastinal Neoplasms 1Liver Cirrhosis 1Hypoxia 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 4pimonidazole 2TH 302 2pembrolizumab 1inositol trispyrophosphate 1gadobutrol 1fluoromisonidazole 1Tirapazamine 1Surgical Procedures, Operative 1Radiotherapy 1Propofol 1Pancreaticoduodenectomy 1Paclitaxel 1Ipilimumab 1Injections 1Gemcitabine 1Ethiodized Oil 1Cisplatin 1Blood Specimen Collection 1Biopsy 1AQ4N 14-methylbenzenesulfonic acid 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × Ethiodized Oil × Gastrointestinal × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡